Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
2 Underrated Weight Loss Stocks to Buy Now
08:00am, Sunday, 08'th Mar 2026
Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.
Roche chairman still expects diagnostics hit from US tariffs
04:23am, Saturday, 07'th Mar 2026
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
12:32pm, Friday, 06'th Mar 2026
RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva®
Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus e
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
03:19am, Friday, 06'th Mar 2026
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial
01:57pm, Thursday, 05'th Mar 2026
Genentech, part of Roche , said on Thursday that its experimental obesity drug helped people lose up to 10.7% of their body weight in a mid-stage study.
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
01:45pm, Thursday, 05'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
01:45pm, Thursday, 05'th Mar 2026
Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 peopl
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
01:15am, Thursday, 05'th Mar 2026
Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.1 Majority of respondents say that con
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
10:21am, Tuesday, 03'rd Mar 2026
RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS.
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports
01:26am, Tuesday, 03'rd Mar 2026
Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk , its CEO told �
Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial
01:58am, Monday, 02'nd Mar 2026
The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS
Basel, 02 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful a
